BlackRock
ARQT icon

BlackRock’s Arcutis Biotherapeutics ARQT Stock Holding History

BlackRock’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$277M Buy
10,545,466
+1,345,055
+15% +$31.3M ﹤0.01% 1595
2026
Q1 		$217M Buy
9,200,411
+100,832
+1% +$2.57M ﹤0.01% 1622
2025
Q4 		$264M Buy
9,099,579
+525,584
+6% +$13.5M ﹤0.01% 1506
2025
Q3 		$162M Buy
8,573,995
+41,234
+0.5% +$650K ﹤0.01% 1797
2025
Q2 		$120M Sell
8,532,761
-359,576
-4% -$5.04M ﹤0.01% 1930
2025
Q1 		$139M Sell
8,892,337
-256,221
-3% -$3.61M ﹤0.01% 1799
2024
Q4 		$127M Buy
9,148,558
+119,002
+1% +$1.3M ﹤0.01% 1941
2024
Q3 		$84M Buy
9,029,556
+406,938
+5% +$4.02M ﹤0.01% 2183
2024
Q2 		$80.2M Buy
8,622,618
+1,963,877
+29% +$17.8M ﹤0.01% 2155
2024
Q1 		$66M Buy
6,658,741
+742,195
+13% +$5.54M ﹤0.01% 2294
2023
Q4 		$19.1M Buy
5,916,546
+1,896,145
+47% +$5.15M ﹤0.01% 3036
2023
Q3 		$21.3M Sell
4,020,401
-210,973
-5% -$1.79M ﹤0.01% 2909
2023
Q2 		$40.3M Sell
4,231,374
-366,898
-8% -$4.07M ﹤0.01% 2624
2023
Q1 		$50.6M Sell
4,598,272
-615,986
-12% -$8.91M ﹤0.01% 2436
2022
Q4 		$77.2M Buy
5,214,258
+132,514
+3% +$2.32M ﹤0.01% 2186
2022
Q3 		$97.1M Buy
5,081,744
+503,591
+11% +$11.4M ﹤0.01% 1986
2022
Q2 		$97.6M Buy
4,578,153
+262,351
+6% +$5.38M ﹤0.01% 2020
2022
Q1 		$83.1M Buy
4,315,802
+1,938
+0% +$32.8K ﹤0.01% 2253
2021
Q4 		$89.5M Buy
4,313,864
+117,938
+3% +$2.35M ﹤0.01% 2284
2021
Q3 		$100M Sell
4,195,926
-52,694
-1% -$1.2M ﹤0.01% 2210
2021
Q2 		$116M Buy
4,248,620
+46,661
+1% +$1.31M ﹤0.01% 2163
2021
Q1 		$122M Buy
4,201,959
+1,306,905
+45% +$40.8M ﹤0.01% 2074
2020
Q4 		$81.4M Buy
2,895,054
+838,668
+41% +$20.5M ﹤0.01% 2199
2020
Q3 		$60.3M Buy
2,056,386
+489,812
+31% +$13.1M ﹤0.01% 2175
2020
Q2 		$47.4M Buy
1,566,574
+701,265
+81% +$20.3M ﹤0.01% 2278
2020
Q1 		$25.8M Buy
+865,309
New +$23.2M ﹤0.01% 2474

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BlackRock's ARQT Position: Q2 2026 in Review

BlackRock increased its Arcutis Biotherapeutics (ARQT) stake by 15% in Q2 2026, buying an estimated $31.3M and bringing the position to 10,545,466 shares worth $277M. The position accounts for ﹤0.01% of the portfolio, ranked #1595.

BlackRock first reported a position in ARQT in Q1 2020 and has held it in 26 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • BlackRock held 10,545,466 shares of Arcutis Biotherapeutics worth $277M as of Q2 2026.
  • BlackRock bought 1,345,055 Arcutis Biotherapeutics shares in Q2 2026, an estimated $31.3M.
  • Arcutis Biotherapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #1595 holding.
  • BlackRock first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 26 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.